ClinicalTrials.gg
RecruitingNCT07944053GATHERUpdated Nov 18, 2026

Group Antenatal Healthcare, Education, and Recovery

An interventional study of group prenatal care in Opioid Use Disorder and Pregnancy, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Health services research

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Planned enrollment
363rd of 1,098
110 · median 56
Started
2026
with 83 others
No phase
571 of 1,223
133 open now
Primary completion
2028-04
later than 229 of 315 live
Registered
1,223rd of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 363rd largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 84 that started in 2026, is one of 571 with no phase, reaches primary completion later than 229 of the 315 other live ones, and was the 1,223rd registered.

Opioid-Related Disorders

1,475 studies on the registry are indexed under Opioid-Related Disorders; 292 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

240 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 212 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 75 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The objective is to evaluate implementation strategies and effectiveness of group prenatal care for women in treatment for opioid use disorder.

03

Conditions studied

  • Opioid Use Disorder
  • Pregnancy

Keywords

  • opioid use disorder
  • implementation
  • pregnancy
  • prenatal care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years of age
  • pregnant and less than 28 weeks of gestation at study enrollment
  • receiving treatment for OUD
  • no major antepartum complications
  • capable of giving
  • willing to be visited by research personnel for up to 12 months post-delivery.

Exclusion criteria

Exclusion Criteria:

  • inability to speak English
  • medical complications of pregnancy which would preclude participation in group care.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Group Prenatal Care

    group prenatal care

    Behavioral: group prenatal care

Interventions

  • Behavioralgroup prenatal care

    Patients will be grouped with other women who are all due to deliver around the same time and receive their routine PNC together during 2-hour group sessions. During the first 30-60 minutes of each group session, patients will measure and record their own weight and blood pressure, and an OB healthcare provider (facilitator) will conduct a brief physical assessment in a private area. This 1-on-1 time is also used for the patient to discuss any private concerns that the patient does not feel to disclose to the group. Following the individual health assessments, the OB provider, co-facilitators, and patients will sit in circle for a discussion. There are a range of educational topics set for each of the ten group sessions, and the content is generally tailored to the participants' gestational age or the age of their infants. Any required blood draws and immunizations will be given at the last 30 minutes of the session, if applicable.

06

What researchers measure

Primary outcomes

  1. Maternal healthcare engagement

    Proportion of expected PNC visit attended

    Time frame: from enrollment to delivery

  2. OUD treatment retention

    OUD treatment retention

    Time frame: from enrollment to delivery

  3. Opioid abstinence

    Percentage of urine/blood/saliva toxicology testing negative for unauthorized opioids and other drugs during pregnancy

    Time frame: from enrollment to delivery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 17 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Apr 2028
CompletionEst.
Aug 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07944053
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Aug 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Taylor Carrubba
Contact
taylor.carrubba@jefferson.edu
215-955-8429
Vanessa Short
Contact
215-955-8429

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion